Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
demecarium
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
Demecarium is a long-acting cholinesterase inhibitor and indirect-acting parasympathomimetic agent primarily used in the treatment of glaucoma. It works by inhibiting both acetylcholinesterase and pseudocholinesterase enzymes, thereby prolonging the action of acetylcholine at parasympathetic neuroeffector junctions. This results in constriction of the iris sphincter muscle (miosis) and ciliary muscle, which facilitates increased outflow of aqueous humor from the eye and reduces intraocular pressure. Demecarium is typically reserved for cases where other antiglaucoma agents are insufficient due to its toxicity profile. The drug has also been used in veterinary medicine to manage glaucoma in dogs[1][2][3][5][6][7].
- Brand names
- HumorsolVisumiotic
- Other names
- demecarium bromideDemekastigmine bromide
02
Targets
ButyrylcholinesteraseAcetylcholinesterase
Beyond the preview
Go deeper on demecarium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on demecarium.